A Phase 1 interventional study of Etrasimod Immediate Release (IR) in Healthy Participants, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to look at how healthy adults process Etrasimod when assessed by wearable sensors. Etrasimod is taken without food and assessments taken by site staff and then by participants after training.
The study is seeking participants who are:
The study will take up to 9 weeks, including the screening period. Participants will have to stay at the study clinic for at least 2 nights, in each of 2 study periods.
Participants will take Etrasimod as a tablet by mouth without food. Blood samples will be taken both before and after participants take Etrasimod. Participants will also use wearable devices to assess blood pressure, heart rate and take further blood samples. A follow-up phone call will be made 20 to 27 days after the last study period.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of etrasimod 2mg tablet under fasted conditions with site staff led assessments and training on how to use wearable sensors followed by single oral dose 2mg tablet under fasted conditions with participant led assessments with wearable sensors.
Drug: Etrasimod Immediate Release (IR)
An immediate release tablet
Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling
AUC0-24 was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by clinical research unit (CRU) staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period
Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling
AUC24hr-last was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
Time frame: 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Maximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling
PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
AUC0-24 of Etrasimod: Tasso and Venous PK Sampling
AUC0-24 was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period
AUC24hr-last of Etrasimod: Tasso and Venous PK Sampling
AUC24hr-last was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
Time frame: 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
AUCinf for Etrasimod: Tasso and Venous PK Sampling
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Cmax for Etrasimod: Tasso and Venous PK Sampling
PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Change From Baseline in Heart Rate (HR) at 1, 2, 3, 4 ,5, 6, 8 and 24 Hours Post-dose on Day 1
Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate electrocardiogram (ECG) HR measurements collected at pre-dose (0 hour) on Day 1 of each period.
Time frame: Baseline; 1, 2, 3 ,4, 5, 6, 8 and 24 hours post-dose on Day 1 of each period
Change From Baseline to Nadir in HR at Day 1
Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate ECG HR measurements collected at pre-dose (0 hour) on Day 1 of each period. Nadir HR was taken as the minimum HR from all ECGs taken post-Etrasimod on day 1 of each period. If Nadir HR was attained at multiple post-dose time points on Day 1, only the latest time point was summarized.
Time frame: Baseline; Anytime or latest time with minimum HR measurement taken post-dose on Day 1 of each period
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of study treatment up to 35 days post last dose of study treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect.
Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Number of Participants With Clinically Significant Findings in Laboratory Abnormalities
Clinical laboratory abnormalities test criteria included, a) hematology: lymphocytes (10\^3/millimeter \[mm)\^3\]) and lymphocytes/leukocytes percentage (%) less than (\<) 0.8\* lower limit of normal (LLN), eosinophils (10\^3/mm\^3), eosinophils/leukocytes (%) and monocytes (10\^3/mm\^3) greater than (\>)1.2\* upper limit of normal (ULN); b) Urinalysis: urine glucose, ketones, urine hemoglobin and bilirubin, leukocyte esterase greater than equal to (\>=) 1. Clinical significance of laboratory abnormalities was determined by the investigator.
Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Number of Participants With Clinically Significant Findings in Vital Signs
Vital signs included blood pressure systolic and diastolic millimeter of mercury (mmHg) and pulse rate (beats/min). Clinical significance of vital signs abnormalities was determined by the investigator.
Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Number of Participants With Clinically Significant Findings in Physical Examination
A complete physical examination test included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination test included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. Clinical significance of physical examination abnormalities was determined by the investigator.
Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Number of Participants Categorized Per Pre-defined Electrocardiogram (ECG) Findings Criteria
ECG findings criteria for QT interval corrected using Fridericia's formula (QTcF) were as: 450 millisecond (msec) \< value less than equal (\<=) 480 msec, 480 msec \< value \<=500 msec, \>500 msec, 30 msec \<= change from baseline \<=60 msec, change from baseline \>60 msec.
Time frame: From Baseline (Day 1) maximum up to Day 17
A total of 8 participants were enrolled in this present study.
| Milestone | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Started | 8 | 0 |
| Treated | 8 | 0 |
| Completed | 7 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Started | 0 | 8 |
| Treated | 0 | 7 |
| Completed | 0 | 6 |
| Not completed | 0 | 2 |
| Withdrew: Assigned but not treated | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
AUC0-24 was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by clinical research unit (CRU) staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
| Nanogram*hour per milliliter (ng*hr/mL ) | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling | 666.4 ± 23 | 745.5 ± 25 |
AUC24hr-last was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
| ng*hr/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling | 768.4 ± 37 | 872.1 ± 16 |
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
| ng*hr/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling | 1503 ± 32 | 1652 ± 19 |
PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.
| Nanogram per milliliter (ng/mL) | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Maximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling | 40.65 ± 26 | 44.63 ± 28 |
AUC0-24 was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
| ng*hr/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) | Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study |
|---|---|---|---|
| AUC0-24 of Etrasimod: Tasso and Venous PK Sampling | 666.4 ± 23 | 745.5 ± 25 | 725.8 ± 21 |
AUC24hr-last was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
| ng*hr/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) | Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study |
|---|---|---|---|
| AUC24hr-last of Etrasimod: Tasso and Venous PK Sampling | 768.4 ± 37 | 872.1 ± 16 | 890.1 ± 31 |
AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
| ng*hr/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) | Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study |
|---|---|---|---|
| AUCinf for Etrasimod: Tasso and Venous PK Sampling | 1503 ± 32 | 1652 ± 19 | 1694 ± 26 |
PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.
| ng/mL | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) | Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study |
|---|---|---|---|
| Cmax for Etrasimod: Tasso and Venous PK Sampling | 40.65 ± 26 | 44.63 ± 28 | 43.18 ± 22 |
Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate electrocardiogram (ECG) HR measurements collected at pre-dose (0 hour) on Day 1 of each period.
| Beats/minute | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Change at 1 hour | -4.9 ± 3.56 | -3.4 ± 1.72 |
| Change at 2 hours | -10.8 ± 4.33 | -10.3 ± 2.75 |
| Change at 3 hours | -10.8 ± 5.44 | -10.9 ± 2.34 |
| Change at 4 hours | -10.8 ± 5.73 | -10.1 ± 3.44 |
| Change at 5 hours | -4.6 ± 4.44 | -2.4 ± 3.46 |
| Change at 6 hours | -7.0 ± 5.58 | -2.0 ± 5.92 |
| Change at 8 hours | -9.0 ± 6.82 | -4.9 ± 4.56 |
| Change at 24 hours | -8.4 ± 4.60 | -1.9 ± 5.01 |
Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate ECG HR measurements collected at pre-dose (0 hour) on Day 1 of each period. Nadir HR was taken as the minimum HR from all ECGs taken post-Etrasimod on day 1 of each period. If Nadir HR was attained at multiple post-dose time points on Day 1, only the latest time point was summarized.
| Beats/ min | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Change From Baseline to Nadir in HR at Day 1 | -14.1 ± 5.14 | -12.1 ± 2.27 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of study treatment up to 35 days post last dose of study treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect.
| Participants | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 7 | 5 |
Clinical laboratory abnormalities test criteria included, a) hematology: lymphocytes (10\^3/millimeter \[mm)\^3\]) and lymphocytes/leukocytes percentage (%) less than (\<) 0.8\* lower limit of normal (LLN), eosinophils (10\^3/mm\^3), eosinophils/leukocytes (%) and monocytes (10\^3/mm\^3) greater than (\>)1.2\* upper limit of normal (ULN); b) Urinalysis: urine glucose, ketones, urine hemoglobin and bilirubin, leukocyte esterase greater than equal to (\>=) 1. Clinical significance of laboratory abnormalities was determined by the investigator.
| Participants | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Number of Participants With Clinically Significant Findings in Laboratory Abnormalities | 0 | 0 |
Vital signs included blood pressure systolic and diastolic millimeter of mercury (mmHg) and pulse rate (beats/min). Clinical significance of vital signs abnormalities was determined by the investigator.
| Participants | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Number of Participants With Clinically Significant Findings in Vital Signs | 0 | 0 |
A complete physical examination test included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination test included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. Clinical significance of physical examination abnormalities was determined by the investigator.
| Participants | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Number of Participants With Clinically Significant Findings in Physical Examination | 0 | 0 |
ECG findings criteria for QT interval corrected using Fridericia's formula (QTcF) were as: 450 millisecond (msec) \< value less than equal (\<=) 480 msec, 480 msec \< value \<=500 msec, \>500 msec, 30 msec \<= change from baseline \<=60 msec, change from baseline \>60 msec.
| Participants | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| 450 msec < Value <= 480 msec | 1 | 0 |
| 480 msec < Value <= 500 msec | 0 | 0 |
| Value > 500 msec | 0 | 0 |
| 30 msec <= Change from baseline <= 60 msec | 0 | 0 |
| Change from baseline > 60 msec | 0 | 0 |
Collected over Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Event | Period 1: Etrasimod 2mg (Treatment F, With Practice Session) | Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) |
|---|---|---|
| Application site irritationGeneral disorders | 4/8 | 0/7 |
| HeadacheNervous system disorders | 1/8 | 2/7 |
| Atrioventricular block first degreeCardiac disorders | 2/8 | 0/7 |
| Puncture site injuryGeneral disorders | 2/8 | 1/7 |
| Abdominal painGastrointestinal disorders | 0/8 | 1/7 |
| Vessel puncture site haematomaGeneral disorders | 0/8 | 1/7 |
| SyncopeNervous system disorders | 0/8 | 1/7 |
| Device issueProduct Issues | 0/8 | 1/7 |
| Influenza like illnessGeneral disorders | 1/8 | 0/7 |
| Burns second degreeInjury, poisoning and procedural complications | 1/8 | 0/7 |
Safety analysis set (SAS) included all participants who took at least 1 dose of study intervention.
| Age, Continuous(Years) | All Participants: Etrasimod 2mg |
|---|---|
| Mean | 42.0 ± 13.70 |
| Sex: Female, Male(Participants) | All Participants: Etrasimod 2mg |
|---|---|
| Female | 4 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | All Participants: Etrasimod 2mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants: Etrasimod 2mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Dec 2023 to primary completion in Mar 2024, 2 months.
Results were first posted in Mar 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.